Imcyse SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Imcyse SA - overview
Established
2010
Location
-, -, Belgium
Primary Industry
Pharmaceuticals
About
Based in Liege, Belgium, and founded in 2011, Imcyse SA provides therapies for severe, chronic autoimmune diseases. In June 2019, Imcyse SA raised EUR 28 million in series B funding led by EQT Life Sciences, with participation from Epimède, SFPI-FPIM, etc. In February 2021, the firm raised EUR 21. 3 million in Series B funding led by investor Pfizer, Inc.
, with participation from returning investors Biogenosis, Epimède, K. U. Leuven Research & Development, Noshaq, SFPI-FPIM, and Société Régionale d'Investissement de Wallonie. As of 2024, Denis Bedoret is the Chief Executive Officer (CEO) of the company.
Imcyse SA provides the Imotope platform, designed to prevent, halt, and potentially cure autoimmune diseases. The company's platform generates cytolytic T cells that specifically target and eliminate abnormal disease pathways without adversely affecting the overall immune system. Imotopes is a small and irregular peptide injections, that prompt an immune response and obstruct autoimmune pathways.
Current Investors
K.U. Leuven Research & Development, EQT Life Sciences, Société Régionale d'Investissement de Wallonie
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals
Website
www.imcyse.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Imcyse SA - timeline of key events
Imcyse SA - financials
| Fiscal Year Ended | Jun 30, 2011 | Jun 30, 2012 | Jun 30, 2013 | Jun 30, 2014 | Jun 30, 2015 | Jun 30, 2016 | Jun 30, 2017 | Jun 30, 2018 | Jun 30, 2019 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | May 21, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - | 83,398 | 453,451 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | 443.7% | - | - | - |
| EBITDA (USD) | 5,603 | (154,482) | (1,220,306) | 1,011,696 | (1,124,917) | (736,642) | (1,433,744) | - | (2,602,540) | (6,031,007) | (2,331,825) | (16,076,066) | - | - | - |
| Operating Income (USD) | 5,603 | (161,224) | (1,240,963) | 681,067 | (1,508,207) | (1,418,804) | (5,365,765) | - | (6,745,700) | (8,691,819) | (6,835,949) | (25,670,104) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | (8196.8%) | (5661.1%) | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - | (2796.0%) | (3545.3%) | - | - | - |
| NET Income (USD) | 2,326 | (163,139) | (1,199,721) | 176,985 | (1,305,412) | (672,805) | (3,674,363) | - | (6,057,429) | (4,042,134) | (5,685,035) | (18,585,691) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - | (6816.8%) | (4098.7%) | - | - | - |
Imcyse SA - employee data
Imcyse SA - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman Of The Board | BM | ||||||
| Chairman of the Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.